The clinical value of the level of serum CA19-9, CA242 combined with ultrasound sonography, #br#
contrast-enhanced ultrasound, PET/CT, CT in the diagnosis of pancreatic cancer
ZHAO Li, LI Ming-xing, ZHOU Jing
Department of Ultrasound Diagnosis, the Affiliated Hospital of Southwest Medical University, Luzhou Sichuan 646000, China
Abstract：Objective: To investigate the clinical value of the level of serum CA19-9, CA242 combined with ultrasound sonography, contrast-enhanced ultrasound, PET/CT, CT in the diagnosis of pancreatic cancer. Methods: A retrospective analysis was performed for the clinical data of 60 patients with pancreatic cancer confirmed by surgical exploration or postoperative pathological examination from January 2014 to March 2017 in the Affiliated Hospital of Southwest Medical University. The levels of serum CA19-9 and CA242 were detected, and ultrasound sonography, contrast-enhanced ultrasound, PET/CT and CT were performed. Results: Compared with the normal, the level of serum CA19-9, CA242 in patients with pancreatic cancer were markedly elevated. The combination of CA19-9 and CA242 could increase the sensitivity in the diagnosis of pancreatic cancer. Combined with the level of serum CA19-9 and CA242, the diagnostic accuracy and sensitivity contrast-enhanced ultrasound or PET/CT were greater than those of ultrasound sonography or CT. There was no significant difference between contrast-enhanced ultrasound and PET/CT in the definitive diagnosis of pancreatic cancer. Conclusion: The combination of CA19-9 and CA242 with contrast-enhanced ultrasound or PET/CT could promote the diagnostic accuracy of pancreatic cancer. Contrast-enhanced ultrasound has advantage in finding the tiny lesions of pancreatic cancer, and PET/CT could diagnose metastasis of pancreatic cancer. Contrast-enhanced ultrasound and PET/CT could help to guide the treatment of pancreatic cancer.
赵 丽，李明星，周 静. CA19-9、CA242联合常规超声、超声造影、PET/CT、#br#
CT在胰腺癌诊断中的临床价值[J]. 中国临床医学影像杂志, 2018, 29(7): 483-485.
ZHAO Li, LI Ming-xing, ZHOU Jing. The clinical value of the level of serum CA19-9, CA242 combined with ultrasound sonography, #br#
contrast-enhanced ultrasound, PET/CT, CT in the diagnosis of pancreatic cancer. JOURNAL OF CHINA MEDICAL IMAGING, 2018, 29(7): 483-485.
[1]Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA, 2015, 65(2): 87-108.
[2]Siegel R, Ward E, Brawley O, et al． Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA, 2011, 61(4): 212-236.
[3]Gillen S, Schuster T, Buschenfelde MZ, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med, 2010, 7(4): e1000267.
[4]Kamisawa T, Wood DL, Itoi T, et al. Pancreatic cancer[J]. Lancet, 2016, 388(1): 73-85.
[5]Petrone MC, Arcidiacono PG. New strategies for the early detection of pancreatic cancer[J]. Exp Rec Gastroneterol Hepatol, 2016, 10(2): 157-159.（下转490页）
（上接485页）
[6]Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2008, 58(1): 71-96.
[7]Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer[J]. Postgrad Med J, 2008, 84(995): 478-497.
[8]张乐之，龚燕芳，屠振兴. 胰腺癌患者血清CA242定量测定及其意义[J]. 胰腺病学，2002，20（1）：20-21．
[9]Li X, Guo X, Li H, et al. Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer[J]. Tumor Biol, 2014, 35(6): 5281-5286．
[10]Postemao M, Gilja OH. Contrast-enhanced and targeted ultrasound[J]. World J Gastroenterol, 2011, 17(1): 28-41．
[11]Rossi S, Ghittoni G, Ravetta V, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detectionand characterization of portal vein thrombosis complicating hepatocellular carcinoma[J]. Eur Radiol, 2008, 18(8): 1749-1756．
[12]刘站，唐少珊. 超声造影评估胰腺癌周围血管受侵程度及可切除性的应用价值[J]. 临床肝胆杂志，2017，33（1）：126-129.
[13]范智慧，严昆，吴薇，等. CEUS定量分析鉴别诊断胰腺癌和肿块型胰腺炎[J]. 中国医学影像技术，2012，28（7）：1354-1358.
[14]Epelbaum R, Frenkel A, Haddad R, et al. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT[J]. J Nucl Med, 2013, 54(1): 12-18．
[15]Sperti C, Pasquali C, Bissoli S, et al. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT[J]. J Gastrointest Surg, 2010, 14(1): 131-140．
[16]Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT[J]. Mol Imaging Biol, 2010, 12(4): 452-459．
[17]Manfredi R, Bonatti M, D’Onofrio M, et al. Incidentally discovered benign pancreatic cystic neoplasms not communicating with the ductal system: MR/MRCP imaging appearance and evolution[J]. Radiol Med, 2013, 118(2): 163-180．
